Medicines & vaccines · Japan

Shionogi

Anti-infectives specialist behind the Xocova (ensitrelvir) COVID-19 antiviral, the Xofluza influenza antiviral and the cefiderocol (Fetroja) antibiotic for resistant gram-negative bacteria.

Headquarters
Osaka, Japan · East Asia
Value chain
Medicines & vaccines(Products)
What that means
Develops and sells therapeutics under its own name: drugs, biologics, vaccines, cell and gene therapies and radiopharmaceuticals.
Founded
1878
Ownership
Listed
Listing
TSE:4507 on Google Finance
Website
shionogi.com
Relevance
Moderate at its strongest, in Advanced Therapeutics, Vaccines & Medical Countermeasures

In 1 capability

Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.

  1. Biotechnology & Health Technologies · Design · listed #24 of 50

    Anti-infectives specialist behind the Xocova (ensitrelvir) COVID-19 antiviral, the Xofluza influenza antiviral and the cefiderocol (Fetroja) antibiotic for resistant gram-negative bacteria.

    Relevance: Anti-infectives specialist

    Source · en.wikipedia.org